Clouth, Johannes; Liepa, Astra M.; Moeser, Guido; … - In: Health Economics Review 8 (2018) 18, pp. 1-10
Objective: To estimate both the number of patients with hepatocellular carcinoma (HCC) eligible annually for second-line therapy following sorafenib in Germany and the healthcare costs accrued by patients meeting eligibility criteria. Methods: Patients with an HCC diagnosis and one or more...